Ask AI
ProCE Banner Activity

Adverse Events With Oral Targeted Therapies for HR+/HER2- Breast Cancer: Nursing Perspectives

Slideset

As oral targeted therapies for HR-positive/HER2-negative breast cancer expand, nurses need practical guidance to identify and manage overlapping adverse events, support treatment adherence, and help patients achieve the full benefit of therapy. These downloadable slides summarize indications, dosing, and administration of approved oral targeted agents along with nursing-focused clinical pearls related to AE monitoring and management.

Released: October 02, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Stemline Therapeutics, Inc.

AstraZeneca

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncology nurses and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify and manage toxicities associated with targeted agents in HR-positive/HER2-negative breast cancer, applying strategies to mitigate these adverse events effectively

  • Educate patients, caregivers, and the multidisciplinary team on evidence-based approaches for monitoring and managing adverse events associated with oral targeted therapies for HR-positive/HER2-negative breast cancer

  • Support adherence/persistence to oral targeted therapies in patients with HR-positive/HER2-negative breast cancer through expert-recommended communication strategies, tools, and resources